Comparative crystal structure analysis of the human EP300 and CBP KIX domains

Area of Science:

• Structural Biology
• Cancer Research
• Drug Discovery

Background:

• Small-cell lung cancer (SCLC) is aggressive with limited treatment options.
• The EP300 KIX domain shows pro-tumorigenic activity in SCLC development and growth.
• Targeting EP300 KIX offers a potential therapeutic strategy for SCLC.

Purpose of the Study:

• To determine the crystal structure of the human EP300 KIX domain.
• To provide a structural basis for developing EP300 KIX inhibitors as SCLC therapeutics.
• To compare the EP300 KIX structure with CBP KIX and identify key differences.

Main Methods:

• X-ray crystallography was used to determine the human EP300 KIX domain structure at 2.9 Å resolution.
• Comparative structural analysis between EP300 KIX and CBP KIX domains.
• Identification of key residue differences and conserved structural features.

Main Results:

• The crystal structure of the human EP300 KIX domain was determined, revealing overall similarity to CBP KIX.
• Nine EP300 KIX residues differ from CBP KIX, including Ala627 which alters surface potential.
• Conserved hydrophobic residues forming the allosteric network in CBP KIX are also present in EP300 KIX.

Conclusions:

• The determined EP300 KIX structure provides a foundation for structure-based drug design.
• Understanding EP300 KIX structural features is crucial for developing targeted SCLC therapies.
• This work facilitates the rational design of small-molecule inhibitors targeting EP300 KIX for SCLC treatment.